ICON (ICLR) Stock Looks Cheap On Cash Flow Yet Rich On Earnings
ICON stock is caught between mixed valuation signals, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside, while traditional market multiples make the shares look expensive and the broader checks lean cautious.
- Over the past 3 years, ICON has delivered a decline of 27.7%, which puts more focus on whether the current price fairly reflects the company’s long term cash flow potential.
- The new multi year collaboration with Anthropic on bringing AI into clinical trials can support expectations for stronger cash generation. However, execution risk around turning AI capabilities into consistent returns may still weigh on how much investors are willing to pay.
- The stock screens as undervalued on the Discounted Cash Flow (DCF) estimate by 28.4%. Yet, with a low value score of 2 out of 6 checks, ICON does not come across as a straightforward bargain on the broader valuation framework.
For investors, the debate is whether the DCF based intrinsic value or the richer looking market multiples end up being the better guide to what ICON is worth today.
Find out why ICON's -2.7% return over the last year is lagging behind its peers.
Does ICON Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model looks at the cash ICON can generate for shareholders over time. ICON currently produces last twelve month free cash flow of about $771.4 million, and the model assumes these cash flows keep growing from this base rather than shrinking.
On these projections, the DCF points to an estimated intrinsic value of about $252 per share, which is above the current market price and indicates the stock screens as 28.4% undervalued. The recent multi year collaboration with Anthropic on AI in clinical trials is one factor used to support the cash flow outlook in the model, which incorporates ongoing growth, even if investors are still hesitant to fully reflect that in the current price.
Based on the cash flow analysis in this model, ICON stock currently appears undervalued relative to the DCF based estimate of intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests ICON is undervalued by 28.4%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Is ICON Getting Expensive on Earnings?
P/E is a useful cross check for ICON because the company is profitable and investors often anchor on earnings based measures for clinical research stocks. ICON currently trades on a P/E of about 79.7x, which is well above the Life Sciences industry average of 36.5x and also higher than the peer group average of 57.2x.
The Fair P/E Ratio for ICON is estimated at 29.5x, based on factors such as its growth outlook, margins, size and risk profile. That is far below the current 79.7x level, which implies the stock carries a rich premium even after allowing for these company specific features and AI related initiatives like the Anthropic collaboration.
On this earnings based yardstick, ICON stock screens as clearly overvalued relative to what the Fair P/E suggests would be reasonable.
See what the numbers say about this price — find out in our valuation breakdown.
The ICON Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where ICON's valuation puzzle leaves off. They lay out the specific assumptions on ICON's future growth, margins and earnings that would need to hold for the stock to be worth materially more or less than today. Each narrative treats fair value as a thesis about ICON's business that you can watch over time instead of a one off snapshot, and they sit on Simply Wall St's Community page.
ICON investors are weighing two sharply different stories that hinge on how durable bookings strength and margin recovery really are.
Bull case: roughly fairly valued
"ICON has demonstrated resilience amidst macro uncertainties by focusing on strategic partnerships and opportunities in the midsized pharma segment, which could contribute to future revenue growth..."
Read the full Bull Case to see why ICON could be undervalued
Bear case: 20% overvalued
"Intensifying price competition, as acknowledged by management and reinforced by large pharma clients under patent cliff pressures, threatens to erode ICON's gross and EBITDA margins in the coming years..."
Read the full Bear Case to see why ICON could be overvalued
Do you think there's more to the story for ICON? Head over to our Community to see what others are saying!
The Bottom Line
ICON sits between a Discounted Cash Flow (DCF) intrinsic value estimate that points to upside and earnings based multiples that flag the stock as overvalued. The gap comes from what each lens emphasises. The DCF focuses on cash generation and capital needs over time, while the richer P/E reflects high growth expectations and current sentiment toward peers. With broader valuation checks still weak, the key question is whether ICON can turn its AI and clinical trial positioning into durable cash flow and margins that justify the current premium, rather than leaving the DCF discount as a possible value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com